Acutaas Chemicals Limited has informed the Exchange about Investor Presentation

Mgmt Guided Margin ImprovementInvestor Communications View source PDF

ACUTAAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+7.2%1-day move

₹2505.00

prior close

₹2554.90

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.8+0.3+5.1+4.9+7.2+6.6+7.1+9.2+9.6+10.2+17.9+20.3+41.2—

Up moveDown movePending

AI summary

Acutaas Chemicals reported exceptional Q4 FY26 results with revenue of Rs. 4,328 million (up 40.3% YoY), EBITDA of Rs. 1,835 million (up 116% YoY), and PAT of Rs. 1,343 million (up 114% YoY). The company achieved its highest-ever quarterly PAT margin of 31.0%, while full-year FY26 revenue grew 33% to Rs. 13,394 million with PAT more than doubling to Rs. 3,564 million. The Executive Chairman highlighted a clear diversification strategy across three verticals: Battery Chemicals, Semiconductors, and Pharmaceutical CDMO, and explicitly guided for 25% revenue growth in FY27.

Likely market impact

Strong margin expansion (EBITDA margin at 35.9%, PAT margin at 26.6%) driven by cost efficiencies and higher CDMO contribution signals improving profitability. The management's explicit 25% revenue growth guidance for FY27 provides a clear forward target for investors, though no specific margin guidance was given.